| scholarly article | Q13442814 |
| P50 | author | Anna Tesei | Q38641349 |
| Chiara Arienti | Q57079239 | ||
| Sara Pignatta | Q57231219 | ||
| Michele Zanoni | Q57231223 | ||
| Michela Tebaldi | Q57231224 | ||
| Gianluca Tedaldi | Q87377375 | ||
| P2093 | author name string | Alberto Del Rio | |
| Silvia Carloni | |||
| P2860 | cites work | IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma | Q21261901 |
| IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance | Q24309891 | ||
| Mechanism of activation and inhibition of the HER4/ErbB4 kinase | Q24310089 | ||
| Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
| IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis | Q24655426 | ||
| Targeting of erbB3 receptor to overcome resistance in cancer treatment | Q26864668 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. | Q27851582 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer | Q27853060 | ||
| Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. | Q27853122 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data | Q29547161 | ||
| Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism | Q29616720 | ||
| The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification | Q29618627 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. | Q33320151 | ||
| Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). | Q33730975 | ||
| ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency | Q33963261 | ||
| HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature | Q34223664 | ||
| Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
| Mechanism of action of trastuzumab and scientific update | Q34437163 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model? | Q35047964 | ||
| MAP kinases and CDKs: kinetic basis for catalytic activation | Q35054246 | ||
| Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma | Q35700713 | ||
| Systemic treatment of gastric cancer. | Q35804239 | ||
| Treatment of metastatic esophagus and gastric cancer | Q35857455 | ||
| Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. | Q35889941 | ||
| The ErbB receptors and their ligands in cancer: an overview. | Q36108987 | ||
| Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer | Q36220464 | ||
| Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer | Q36408570 | ||
| Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer | Q36472437 | ||
| A helix scaffold for the assembly of active protein kinases | Q36871421 | ||
| Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies | Q37143534 | ||
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways | Q37425090 | ||
| Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). | Q37567784 | ||
| Mechanisms of resistance to HER family targeting antibodies | Q37671920 | ||
| An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models | Q37690880 | ||
| Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. | Q37877173 | ||
| Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology | Q38072265 | ||
| Different genome organization in two new cell lines established from human gastric carcinoma. | Q38502122 | ||
| Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance | Q38860383 | ||
| Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers | Q38867798 | ||
| Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome | Q39036776 | ||
| The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis | Q39160504 | ||
| Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. | Q39416858 | ||
| Resistance to EGFR-targeted therapy: a family affair | Q39589553 | ||
| Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | Q40613157 | ||
| Identification of cadherin-11 down-regulation as a common response of astrocytoma cells to transforming growth factor-alpha | Q40818375 | ||
| Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells | Q40887267 | ||
| Molecular genetics and in vitro sensitivity of a new human cell line, KKP, from a gastric adenocarcinoma. | Q41019667 | ||
| Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer | Q44978934 | ||
| HER-2 amplification is highly homogenous in gastric cancer. | Q51779078 | ||
| SLUG silencing increases radiosensitivity of melanoma cells in vitro. | Q53128776 | ||
| Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. | Q53598605 | ||
| Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. | Q53645618 | ||
| Early HER2 dysregulation in gastric and oesophageal carcinogenesis | Q58003579 | ||
| Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer | Q60056795 | ||
| Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck | Q71767596 | ||
| The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen | Q83858971 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 18424-18439 | |
| P577 | publication date | 2016-04-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer | |
| P478 | volume | 7 |
| Q64929541 | Anti-tumor Efficacy Assessment of the Sigma Receptor Pan Modulator RC-106. A Promising Therapeutic Tool for Pancreatic Cancer. |
| Q50053443 | Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer. |
| Q53701966 | Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab. |
| Q57072196 | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
| Q92073891 | Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer |
| Q52560262 | Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q89795555 | Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives |
| Q49497675 | Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down |
| Q58553403 | Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) |
| Q33696201 | Molecular classifications of gastric cancers: Novel insights and possible future applications |
| Q55261916 | Prognostic implications of HER2 heterogeneity in gastric cancer. |
| Q55603677 | Proposed Molecular and miRNA Classification of Gastric Cancer. |
| Q38703402 | Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance |
| Q47100522 | Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. |
| Q48549971 | miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer |
Search more.